Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 7DiBV | 7DiBV30 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 30 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| V82A, L90M | L33I, G73S | L10I, I62V, L63P, A71V, I93L |
| >7DiBV30| 53 | codons 1-99 | clone 53 PQITLWQRPIVTIKIGGQLKEALLDTGAGDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| 54 | codons 1-99 | clone 54 PQITLWQRPLVTVRIGGQLKEALLDTGADDTVIEEINLPGRWKPKIIGGIGGFIKVRQYD QVPIEICGHKTTSTVLVGPTPVNIIGRNLMTQLGCTLNF >7DiBV30| 57 | codons 1-99 | clone 57 PQITLWQRPLVTVRIGGQLKEALLDTGADDTVIEEINLPGRWKPKIIGGIGGFIKVRQYD QVPIEICGHKVISTALVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| 59 | codons 1-99 | clone 59 PQITLWQRPIVTIKIGGQLKEALLDTGADGTVIEEMNLPGRWKPIMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGKNPMTQLGCTLNF >7DiBV30| 60 | codons 1-99 | clone 60 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| 61 | codons 1-99 | clone 61 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICEHKVISTVLVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| 62 | codons 1-99 | clone 62 PQITLWQRPIVTIKTGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| 64 | codons 1-99 | clone 64 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQLGCTLNF >7DiBV30| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQLGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |